TRANSCRIPTOME 2002: From Functional Genomics to Systems
Breaking the Bottle Neck of Genomics and Proteomics
Moncef Jendoubi, Milagen, Inc., Richmond, CA
While the genomics and proteomics fields are actively expanding, there is a need for the biotech industry to find new ways to detect, diagnose, understand and treat human diseases. Milagen has developed a unique antibody-based approach to directly correlate gene products to disease. Based on proprietary technologies globally referred to as ANTIBIOMIX TM, Milagen has generated up to 61,000 high affinity specific polyclonal antibodies to known and unknown human gene products, and is set up to generate antibodies to all human proteins. Within our oncology program, we have used antibody libraries to screen hundreds of matching normal and tumor protein samples, derived from cancer patient tissues and biological fluids, using our proprietary matrix protein array technology. When applied to colon, prostate and breast cancer, dozens of antibodies tested showed a differential protein expression profile between normal and cancer samples. Several validated targets have been identified so far, including secreted molecules in sera. With ANTIBIOMIX TM, antibodies are serving as tools to bridge the gap between the genotype (gene sequence) and the phenotype (disease state). This approach will lead to the rapid identification of a variety of disease specific proteins, and to the validation of novel targets for diagnostic and therapeutic applications.
Return to Table of Contents * Speaker Abstracts * Poster Abstracts * View the Photos
Return to Meetings Home Page
This site produced by the Human Genome Management Information System of Oak Ridge National Laboratory.